Activating ALK mutations, especially F1174L, frequently co-occur with MYCN amplification, synergistically accelerating neuroblastoma progression (Schönherr et al., 2012; Zhu et al., 2012; Hasan et al., 2013). Here, ALK is linked to neuroblastoma.